Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19)Kinuko Hirose, Kanji Sugita, Takeshi Inukai et al.|Blood|2010Cited by 39
Association of aberrant<i>ASNS</i>imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALLAtsushi Watanabe, Takeshi Inukai, Louise van der Weyden et al.|Blood|2020Cited by 23
Resistance of t(17;19)‐acute lymphoblastic leukemia cell lines to multiagents in induction therapyAtsushi Watanabe, Kanji Sugita, Takeshi Inukai et al.|Cancer Medicine|2019Cited by 22
Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptorsXiaoliu Zhang, K Sugita, Takeshi Inukai et al.|Leukemia|2012Cited by 17
Specific induction of CD33 expression by E2A–HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factorKoshi Akahane, K Sugita, Takeshi Inukai et al.|Leukemia|2010Cited by 14